FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nynke Kalkers

Research Profile

Disorders

Concepts & Ideas

Procedures

Physiology

Anatomy

Chemicals & Drugs

Riluzole

Co-author Network

Publications

TOP 3
Nynke F Kalkers; Rob L M Strijers; M M S Jasperse; V Neacsu; Jeroen J G Geurts; Frederik Barkhof; Chris H Polman; Cornelis Stam
Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI.
jasperse bas; Arjan Minneboo; Vincent de Groot; Nynke F Kalkers; Paul E van Helden; Bernard Uitdehaag; Frederik Barkhof; Chris H Polman
Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis.
Stephan C J Huijbregts; Nynke F Kalkers; Leo De Sonneville; Vincent de Groot; Chris H Polman
Cognitive impairment and decline in different MS subtypes.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nynke Kalkers (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Nynke F Kalkers; Rob L M Strijers; M M S Jasperse; V Neacsu; Jeroen J G Geurts; Frederik Barkhof; Chris H Polman; Cornelis Stam
Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2007;118(6):1332-40.
2007: jasperse bas; Arjan Minneboo; Vincent de Groot; Nynke F Kalkers; Paul E van Helden; Bernard Uitdehaag; Frederik Barkhof; Chris H Polman
Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis.
Archives of neurology 2007;64(2):190-4.
2006: Stephan C J Huijbregts; Nynke F Kalkers; Leo De Sonneville; Vincent de Groot; Chris H Polman
Cognitive impairment and decline in different MS subtypes.
Journal of the neurological sciences 2006;245(1-2):187-94.
2005: SJ Camp; Valerie L Stevenson; Alan J Thompson; Gordon T Ingle; David H Miller; C Borras; B Brochet; V Dousset; M Falautano; Massimo Filippi; Nynke F Kalkers; Xavier Montalban; Chris H Polman; DW Langdon
A longitudinal study of cognition in primary progressive multiple sclerosis.
Brain : a journal of neurology 2005;128(Pt 12):2891-8.
2005: Jaume Sastre-Garriga; Gordon T Ingle; Marco Rovaris; Nieves Téllez; jasperse bas; Daniel R Altmann; B Benedetti; Valerie L Stevenson; Mara Cercignani; Siobhan M Leary; Frederik Barkhof; B Brochet; V Dousset; Massimo Filippi; Xavier Montalban; Nynke F Kalkers; Chris H Polman; Alex Rovira; David H Miller; Alan J Thompson
Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data.
Neurology 2005;65(4):633-5.
2005: Joep Killestein; Nynke F Kalkers; Chris H Polman
Glutamate inhibition in MS: the neuroprotective properties of riluzole.
Journal of the neurological sciences 2005;233(1-2):113-5.
2005: M Judith Eikelenboom; Joep Killestein; Thijs Izeboud; Nynke F Kalkers; Paul A Baars; René A W van Lier; Frederik Barkhof; Bernard Uitdehaag; Chris H Polman
Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS.
Journal of neuroimmunology 2005;158(1-2):222-30.
2004: S C J Huijbregts; Nynke F Kalkers; Leo De Sonneville; Vincent de Groot; I E W Reuling; Chris H Polman
Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.
Neurology 2004;63(2):335-9.
2004: A Cecile J W Janssens; Josien B de Boer; Nynke F Kalkers; Jan Passchier; Pieter A Van Doorn; Rogier Q Hintzen
Patients with multiple sclerosis prefer early diagnosis.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2004;11(5):335-7.
2004: E L J Hoogervorst; Nynke F Kalkers; Gary R Cutter; Bernard Uitdehaag; Chris H Polman
The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite.
Multiple sclerosis (Houndmills, Basingstoke, England) 2004;10(1):55-60.
2003: Tineke Van Veen; Hans M Schrijver; Antoon Zwiers; J B A Crusius; Dirk L Knol; Nynke F Kalkers; Marja L Laine; Frederik Barkhof; Amado Salvador Peña; Chris H Polman; Bernard Uitdehaag
The interleukin-1 gene family in multiple sclerosis susceptibility and disease course.
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(6):535-9.
2003: Tineke Van Veen; Lisa van Winsen; J B A Crusius; Nynke F Kalkers; Frederik Barkhof; Amado Salvador Peña; Chris H Polman; Bernard Uitdehaag
[Alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype.
Neurology 2003;61(9):1245-9.
2003: Joep Killestein; M Judith Eikelenboom; Thijs Izeboud; Nynke F Kalkers; Herman J Adèr; Frederik Barkhof; René A W van Lier; Bernard Uitdehaag; Chris H Polman
Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS.
Journal of neuroimmunology 2003;142(1-2):141-8.
2003: A Cecile J W Janssens; Pieter A Van Doorn; Josien B de Boer; Nynke F Kalkers; F G A van der Meche; Jan Passchier; Rogier Q Hintzen
Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(4):397-403.
2002: Nynke F Kalkers; Frederik Barkhof; Elisabeth Bergers; Ronald A van Schijndel; Chris H Polman
The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(6):532-3.
2002: M Judith Eikelenboom; Joep Killestein; Thijs Izeboud; Nynke F Kalkers; René A W van Lier; Frederik Barkhof; Bernard Uitdehaag; Chris H Polman
Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis.
Journal of neuroimmunology 2002;133(1-2):225-32.
2002: Nynke F Kalkers; Najim Ameziane; Joost C J Bot; Arjan Minneboo; Chris H Polman; Frederik Barkhof
Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.
Archives of neurology 2002;59(10):1572-6.
2002: Nynke F Kalkers; Hugo Vrenken; Bernard Uitdehaag; Chris H Polman; Frederik Barkhof
Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(5):410-4.
2002: Bernard Uitdehaag; Herman J Adèr; T J A Roosma; Vincent de Groot; Nynke F Kalkers; Chris H Polman
Multiple sclerosis functional composite: impact of reference population and interpretation of changes.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(5):366-71.
2002: Bernard Uitdehaag; H J Adèr; Nynke F Kalkers; C H Polman
Quantitative functional measures in MS: what is a reliable change?
Neurology 2002;59(4):648-9; author reply 649.
2002: Tineke Van Veen; Nynke F Kalkers; J B A Crusius; Lisa van Winsen; Frederik Barkhof; Peter J H Jongen; Amado Salvador Peña; Chris H Polman; Bernard Uitdehaag
The FAS-670 polymorphism influences susceptibility to multiple sclerosis.
Journal of neuroimmunology 2002;128(1-2):95-100.
2002: Joep Killestein; E L J Hoogervorst; Marcus Reif; Nynke F Kalkers; Andre C D van Loenen; P G M Staats; Robert W Gorter; Bernard Uitdehaag; Chris H Polman
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Neurology 2002;58(9):1404-7.
2002: Brigit A de Jong; Tom W J Huizinga; E L E M Bollen; Bernard Uitdehaag; Gerlof P Th Bosma; Mark A Van Buchem; Edmond J Remarque; Alexandra C S Burgmans; Nynke F Kalkers; Chris H Polman; Rudi G J Westendorp
Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis.
Journal of neuroimmunology 2002;126(1-2):172-9.
2002: Gordon T Ingle; Valerie L Stevenson; David H Miller; Siobhan M Leary; Marco Rovaris; Frederik Barkhof; B Brochet; V Dousset; Massimo Filippi; Xavier Montalban; Nynke F Kalkers; Chris H Polman; Alex Rovira; Alan J Thompson
Two-year follow-up study of primary and transitional progressive multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(2):108-14.
2002: E L J Hoogervorst; Nynke F Kalkers; Bernard Uitdehaag; Chris H Polman
A study validating changes in the multiple sclerosis functional composite.
Archives of neurology 2002;59(1):113-6.
2001: Nynke F Kalkers; Elisabeth Bergers; Jonas A Castelijns; Marianne A A van Walderveen; Joost C J Bot; Herman J Adèr; Chris H Polman; Frederik Barkhof
Optimizing the association between disability and biological markers in MS.
Neurology 2001;57(7):1253-8.
2001: E L J Hoogervorst; Nynke F Kalkers; Bernard Uitdehaag; Chris H Polman
Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(5):335-9.
2001: Joep Killestein; Nynke F Kalkers; Jan F Meilof; Frederik Barkhof; René A W van Lier; Chris H Polman
TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS.
Neurology 2001;57(6):1129-31.
2001: JB Boringa; R H C Lazeron; I E W Reuling; Herman J Adèr; Lilian E M A Pfennings; Jaap Lindeboom; Leo De Sonneville; Nynke F Kalkers; Chris H Polman
The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice.
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(4):263-7.
2001: E L J Hoogervorst; Lisa van Winsen; M Judith Eikelenboom; Nynke F Kalkers; Bernard Uitdehaag; Chris H Polman
Comparisons of patient self-report, neurologic examination, and functional impairment in MS.
Neurology 2001;56(7):934-7.
2001: Nynke F Kalkers; Rogier Q Hintzen; Jan-Hein T M van Waesberghe; R H C Lazeron; Ronald A van Schijndel; Herman J Adèr; Chris H Polman; Frederik Barkhof
Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy.
Journal of the neurological sciences 2001;184(2):155-62.
2001: Nynke F Kalkers; L Bergers; Vincent de Groot; R H C Lazeron; Marianne A A van Walderveen; Bernard Uitdehaag; Chris H Polman; Frederik Barkhof
Concurrent validity of the MS Functional Composite using MRI as a biological disease marker.
Neurology 2001;56(2):215-9.
2000: Nynke F Kalkers; Vincent de Groot; R H C Lazeron; Joep Killestein; Herman J Adèr; Frederik Barkhof; Gustaaf J Lankhorst; Chris H Polman
MS functional composite: relation to disease phenotype and disability strata.
Neurology 2000;54(6):1233-9.